Press coverage about Stemline Therapeutics (NASDAQ:STML) has been trending somewhat negative on Sunday, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Stemline Therapeutics earned a coverage optimism score of 0.00 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 47.3526054192954 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

Stemline Therapeutics (NASDAQ STML) opened at $16.60 on Friday. The firm has a market capitalization of $451.96, a price-to-earnings ratio of -6.46 and a beta of -0.02. Stemline Therapeutics has a 12 month low of $5.50 and a 12 month high of $17.40.

Stemline Therapeutics (NASDAQ:STML) last posted its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.11). Stemline Therapeutics had a negative return on equity of 88.09% and a negative net margin of 5,362.77%. equities analysts expect that Stemline Therapeutics will post -2.68 earnings per share for the current year.

Several research analysts have recently weighed in on the company. Zacks Investment Research upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, January 5th. ValuEngine upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. BidaskClub upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Finally, HC Wainwright set a $38.00 price target on Stemline Therapeutics and gave the stock a “buy” rating in a research note on Thursday, December 14th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $33.75.

In related news, COO Kenneth Hoberman sold 11,943 shares of the stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $14.18, for a total transaction of $169,351.74. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider David Gionco sold 4,250 shares of the stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $13.43, for a total value of $57,077.50. The disclosure for this sale can be found here. Insiders have sold a total of 42,216 shares of company stock valued at $591,925 in the last quarter. 16.70% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Somewhat Negative Media Coverage Somewhat Unlikely to Affect Stemline Therapeutics (STML) Stock Price” was first published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with's FREE daily email newsletter.